Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

Positive Initial Results for Novel COVID-19 Drug Molnupiravir First Tested at Sheba

Studies indicate a quicker decline in the infectious virus among individuals with early COVID-19 treated with Molnupiravir

According to U.S. drugmaker Merck & Co Inc., initial results of studies on the experimental antiviral drug Molnupiravir it is developing with Ridgeback Bio suggest a reduction in the required duration for a negative COVID-19 indication from nasopharyngeal swab tests applied to study participants with early symptomatic COVID-19.

Sheba Medical Center was the first hospital in the world to collaborate with Merck & Co, Inc. and conduct a clinical trial of Molnupiravir on COVID-19, which was originally designed to combat the flu. Molnupiravir works by causing mutations in the enzyme responsible for replicating the virus.

Presently, Molnupiravir is in Phase II/III clinical trials, set to be completed by May.
“We are very pleased to share our initial Phase II infectivity data. At a time where there is an unmet need for antiviral treatments against COVID-19, we are encouraged by these preliminary data,” said Dr. Wendy Painter, Chief Medical Officer of Ridgeback Bio.

Sheba's Legacy of Hope: Alexandra's Remarkable Road to Wellness
Last month, a celebratory atmosphere filled the halls of the Edmond and Lily Safra Children’s Hospital at Sheba. The occasion marked a significant milestone in…
Read More
Kerry's Fight Against Skin Cancer at Sheba
Looking back at 2020, 55-year-old Kerry Louise Matthews was in love with her life. Despite the pandemic, the UK native had just started on a…
Read More
Sheba Ranked Among the Top 10 Hospitals in the World by Newsweek
We are pleased to announce that for the sixth consecutive year, Sheba has been recognized as one of the best hospitals in the world by…
Read More